Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06148584
Other study ID # HPTN 111
Secondary ID UM1AI068619-17
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date March 13, 2024
Est. completion date April 30, 2025

Study information

Verified date April 2024
Source HIV Prevention Trials Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To test community-based approaches to engage heterosexual men at risk for HIV and specifically to assess the feasibility and acceptability of a barbershop based HIV prevention program.


Description:

HPTN 111/TRIM is a cluster randomized study to assess the feasibility and acceptability of a barbershop-based HIV prevention program. Eighteen barbershops in Kalangala District, Uganda will be purposively selected to participate in the study and randomized 2:1 to provide the barbershop-based HIV prevention initiative (intervention) or the standard-of-care (control). Individual participants will be enrolled from the barbershops and receive intervention or control services based on their barbershop. The barbershop-based HIV prevention initiative will include barber provided status-neutral HIV education, HIV self-test kits, and information about where to receive HIV prevention services.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 250
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 16 Years and older
Eligibility Inclusion Criteria: Persons who identify as a heterosexual male and meet all of the following criteria are eligible for inclusion in this study: 1. Age = 16 years a. Any participants 16-17 years old will be enrolled following the Uganda National Council for Science and Technology (UNCST) guidelines for mature and emancipated minors 2. Able and willing to provide informed consent 3. Behaviorally vulnerable to HIV, based on self-report of at least one of the following in the last three months: 1. Had condomless sex with a person of unknown HIV status or a person living with HIV 2. Had more than one sexual partner 4. HIV negative per Ugandan Ministry of Health guidelines and the Study-specific Procedures (SSP) Manual 5. Is a regular customer at a participating barbershop as defined in the SSP Manual Exclusion Criteria: Persons who meet any of the following criteria will be excluded from this study: 1. Not planning to stay in the study catchment area in the next 12 months 2. Any other condition that in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. Participants who report sex with other men will not be excluded from this study so long as they meet the inclusion and exclusion criteria listed above.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
General, status-neutral HIV education
General, status-neutral HIV education
Diagnostic Test:
HIV self-test kits
HIV self-test kits
Other:
Information about where to receive HIV prevention services
Information about where to receive HIV prevention services
Behavioral:
Barber-led peer support group education
Barber-led peer support group education
Facility-based HIV risk reduction counseling
Facility-based HIV risk reduction counseling
Diagnostic Test:
Facility-based HIV testing
Facility-based HIV testing
Other:
Information about facility distributed HIV self-test kits
Information about facility distributed HIV self-test kits
Diagnostic Test:
STI testing
STI testing

Locations

Country Name City State
Uganda MU-JHU Research Collaboration (MUJHU CARE LTD) CRS Kampala

Sponsors (3)

Lead Sponsor Collaborator
HIV Prevention Trials Network Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Participant responses from surveys at Week 26 and Week 52 about acceptability of the intervention Week 26 and Week 52
Primary To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Barber responses from surveys about feasibility and acceptability of intervention Week 13, Week 26, Week 39, Week 52, Week 65
Primary To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Recruitment rates during enrollment and retention in study and barbershop activities at Week 26 and Week 52 Week 26 and Week 52
Primary To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Frequency of barber-participant interactions Week 13, Week 26, Week 39, Week 52, Week 65
Primary To evaluate the feasibility and acceptability of a barbershop based HIV prevention initiative Consistent with this primary study objective, the following endpoint will be assessed from participants in the intervention group: Proportion of barber-participant interactions that include delivery of the intervention Week 13, Week 26, Week 39, Week 52, Week 65
Secondary To compare completion of self-initiated HIV testing between intervention and control groups Consistent with this secondary study objective, the following endpoint will be assessed: Self-report of HIV test conducted between enrollment and study visit at Week 26, and between the Week 26 and Week 52 study visits Week 26 and Week 52
Secondary To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported risk behaviors at Week 26 and Week 52, including condom use Week 26 and Week 52
Secondary To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported risk behaviors at Week 26 and Week 52, including number of total sexual partners Week 26 and Week 52
Secondary To evaluate the preliminary effectiveness of the intervention on change in risk behaviors associated with HIV acquisition Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported risk behaviors at Week 26 and Week 52, including number of new sexual partners Week 26 and Week 52
Secondary To compare interest in or use of HIV prevention services between intervention and control groups Consistent with this secondary study objective, the following endpoint will be assessed: Voluntary medical male circumcision (VMMC) during the study Week 26 and Week 52
Secondary To compare interest in or use of HIV prevention services between intervention and control groups Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported referral to PEP care or use of PEP Week 26 and Week 52
Secondary To compare interest in or use of HIV prevention services between intervention and control groups Consistent with this secondary study objective, the following endpoint will be assessed: Self-reported referral to PrEP care or use of any PrEP method during the study Week 26 and Week 52
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2